ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

Abbott Buys AP214 Hormone From Action Pharma For $110 Million

DOW JONES NEWSWIRES Abbott Laboratories (ABT) took another step to enhance its renal-care pipeline by agreeing to acquire AP214, a hormone analogue that may prevent acute kidney injury during cardiac surgery, from Action Pharma A/S for $110 million in cash. The health-care company has been on a buying spree in recent years in order to reduce its dependence on the anti-inflammatory Humira as the drug's U.S. patent expires in late 2016. Abbott also is in the midst of separating into two publicly traded companies: a medical-products business and a pharmaceutical company to be named AbbVie. Abbott will acquire all global rights to develop and market AP214, and will be responsible for funding all future development and commercialization activities. No later milestone payments or royalties will be paid to the Danish biotech company Action Pharma. Abbott currently has two investigational treatments in development for chronic kidney disease: Bardoxolone, which is in Phase 3 development with Reata Pharmaceuticals, and Atrasentan, a compound discovered by Abbott being evaluated in a Phase 2b study. -By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

Stock News for Abbott Labs (ABT)
DateTimeHeadline
09/28/201617:06:44Statement of Changes in Beneficial Ownership (4)
09/28/201609:00:00Abbott Receives FDA Approval for the FreeStyle Libre Pro™ System, a...
09/27/201606:02:29Notice of Effectiveness (effect)
09/26/201613:46:24Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)
09/21/201614:00:00Malnutrition Adds $15.5 Billion Annually to Direct U.S. Medical...
09/21/201610:37:00Abbott Laboratories to Delist from London Stock Exchange
09/21/201609:00:00Abbott Hosts Conference Call for Third-Quarter Earnings
09/20/201616:59:49Registration Statement for Securities to Be Issued in Business...
09/20/201609:00:00Fueling Performance with Fat: EAS® Launches First Ketogenic...
09/17/201603:02:00J&J to Buy Abbott Eye Business -- WSJ
09/16/201618:26:00J&J to Buy Abbott's Eye-Surgery Unit for $4.325 billion -- 3rd...
09/16/201617:55:00J&J to Buy Abbott's Eye-Surgery Unit for $4.325 billion -- 2nd...
09/16/201617:03:04Current Report Filing (8-k)
09/16/201615:59:00J&J to Buy Abbott's Eye-Surgery Unit for $4.325 billion -- Update
09/16/201615:00:00Abbott to Sell Abbott Medical Optics to Johnson & Johnson for...
09/16/201613:20:00J&J Nears Deal to Buy Abbott's Eye-Surgery Unit
09/16/201613:07:00J&J Nears Deal to buy Abbott's Eye-Surgery Equipment Unit
09/15/201609:00:00Abbott Declares 371st Consecutive Quarterly Dividend
09/13/201617:26:56Registration Statement for Securities to Be Issued in Business...
09/08/201613:11:00Abbott Named Industry Leader for Responsible and Sustainable...

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad